4 completed, 1 not yet recruiting, 1 terminated. 2 Phase 4, 1 Not applicable, 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 2 | Completed 1, Not yet recruiting 1 |
| Not applicable | 1 | Completed 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Terminated 1 |
Follow Nonarteritic Anterior Ischemic Optic Neuropathy: new trials by email Literature Review of Nonarteritic Anterior Ischemic Optic Neuropathy trials Research Report on Nonarteritic Anterior Ischemic Optic Neuropathy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Emerging Indications for Hyperbaric Oxygen Treatment Hyperbaric oxygen treatment (HBOT), 100% Oxygen - Post-COVID-19 Condition, Ulcerative Colitis | Phase 4 | Not yet recruiting | Jay C. Buckey Jr. | 100 | 2026-11-01 | 2026-09-09 |
| Platelet-Rich Plasma for Acute Nonarteritic Anterior Ischemic Optic Neuropathy: A Prospective Randomized Controlled Study Autologous Platelet-Rich Plasma (PRP) - Nonarteritic Anterior Ischemic Optic Neuropathy | Not applicable | Completed | Uludag University | 31 | 2022-01-01 | 2026-01-09 |
| Efficacy & Safety of RPh201 Treatment in Patients With Previous Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) RPh201 Cohort A, Placebo Cohort A, RPh201 Cohort B - Nonarteritic Anterior Ischemic Optic Neuropathy | Phase 2 | Terminated | Regenera Pharma Ltd | 165 | 2018-07-10 | 2020-10-12 |
| A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors PDE5 Inhibitors - Nonarteritic Anterior Ischemic Optic Neuropathy | Completed | Eli Lilly and Company | 345 | 2010-05-01 | 2018-04-05 | |
| Ranibizumab Therapy for Non-arteritic Ischemic Optic Neuropathy ranibizumab - Nonarteritic Anterior Ischemic Optic Neuropathy | Phase 1 | Completed | University of Colorado, Denver | 2 | 2007-11-01 | 2016-09-30 |
| Effect of Levodopa-Carbidopa on Visual Function in Patients With Recent-Onset Nonarteritic Anterior Ischemic Optic Neuropathy levodopa-carbidopa - Nonarteritic Anterior Ischemic Optic Neuropathy | Phase 4 | Completed | Shahid Beheshti University of Medical Sciences | 2002-06-01 | 2008-10-20 |
Optic Neuropathy, Ischemic (6) · Calciphylaxis (1) · Colitis, Ulcerative (1) · Craniocerebral Trauma (1) · Crohn Disease (1) · Enterocolitis, Pseudomembranous (1) · Epidermolysis Bullosa (1) · Frostbite (1) · Graft vs Host Disease (1) · Hypospadias (1) · Invasive Fungal Infections (1) · Multiple Sclerosis (1) · Myositis, Inclusion Body (1) · Osteonecrosis (1) · Pouchitis (1)
Cardiovascular Diseases (6) · Cranial Nerve Diseases (6) · Eye Diseases (6) · Nervous System Diseases (6) · Optic Nerve Diseases (6) · Vascular Diseases (6) · Arterial Occlusive Diseases (1) · Autoimmune Diseases (1) · Autoimmune Diseases of the Nervous System (1) · Bacterial Infections (1) · Bacterial Infections and Mycoses (1) · Bone Diseases (1) · Calcinosis (1) · Calcium Metabolism Disorders (1) · Clostridium Infections (1)
Cottonseed Oil (1) · Oxygen (1) · Phosphodiesterase 5 Inhibitors (1) · Ranibizumab (1) · Sildenafil Citrate (1) · Tadalafil (1) · Vardenafil Dihydrochloride (1) · carbidopa, levodopa drug combination (1)
Eli Lilly and Company (1) · Jay C. Buckey Jr. (1) · Regenera Pharma Ltd (1) · Shahid Beheshti University of Medical Sciences (1) · Uludag University (1) · University of Colorado, Denver (1)
United States (3) · Iran (1) · Turkey (Türkiye) (1)
Jay Buckey (1) · Leonard A Levin, M.D., Ph.D. (1) · Mohammad Pakravan, MD (1) · Naresh Mandava, MD (1) · Selim Doganay, MD (1)